Huntington Disease, also known as Huntington’s chorea, is an autosomal dominant inherited rare disorder that causes progressive degeneration of nerve cell of brain, leading to deterioration of a person’s physical and mental abilities. Huntington Disease symptoms are usually detected at the age of 30-50 and gets worse over 10 to 25 year period from the onset of disease.
Growth of the Huntington’s Disease Treatment Market is driven by rising prevalence of disease and increasing R&D programs by institutes and universities. According to Huntington’s disease Society of America, there are approximately 30,000 symptomatic people in the U.S. and over 200,000 at-risk of inheriting the disease. Organization such as CHID Foundation, Hereditary Disease Foundation, Huntington's Disease Society of America, and International Huntington Association aid in creating awareness among patients and their family, which is also expected to support growth of the Huntington’s disease treatment market.
Key Competitors in the Huntington Disease Treatment Industry:
1) Bausch Health Companies Inc.
Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International, Inc.) is a Canadian multinational specialty pharmaceutical company. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products. The company was founded in the year 1959, and the headquarters are located in Laval, Quebac, Canada. The company was founded by Milan Panic.
2) SOM Innovation Biotech.
SOM Biotech is a private pharmaceutical company focused on the accelerated discovery and development of therapies for orphan diseases through a proprietary artificial intelligence-based drug discovery technology and developing strategic partnerships with major research centers and pharmaceutical companies. The company was founded in the year 2009, and the headquarters are located in Barcelona, Spain.
As of May 2022, SOM Biotech announced that it has signed a licensing agreement with the University of Minnesota, following the completion of research under a sponsored research agreement.
3) Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. (also known as Teva Pharmaceuticals) is an Israeli multinational pharmaceutical company Commission of autoimmune diseases, from the European. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. Teva's facilities are located in Israel, North America, Europe, Australia, and South America. The company was founded in the year 1901, and the headquarters are located in Tel Aviv, Israel.